ログイン
ランキング
お知らせ
ログイン
文献詳細
増大特集 認知症の危険因子と防御因子
文献概要
うつ病や双極性障害が認知症の危険因子であることは多くの疫学的調査によって示されているが，その生物学的背景には脳血管障害やグルココルチコイドなどが関係しあった機序があると推察される。うつ病や双極性障害の発症や再発を予防することで一部の認知症の発症を抑制・遅延できると考えられるが，食生活や運動などの見直しのほか，最近は抗うつ薬やリチウムの認知症予防効果の可能性が示唆され，今後の介入研究が期待される。
参考文献
1)朝田 隆: 厚生労働科研費補助金 認知症対策事業 平成23年度〜平成24年度 総合研究報告書. 2013
2)Barnes DE, Yaffe K: The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10: 819-828, 2011
3)馬場 元: 認知症の前駆状態としてのうつ病の鑑別と対応. 臨床精神医学42: 961-968, 2013
4)Wragg RE, Jeste DV: Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 146: 577-587, 1989
5)Cummings JL, Miller B, Hill MA, Neshkes R: Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type. Arch Neurol 44: 389-393, 1987
6)McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872, 2005
7)Kessing LV, Nilsson FM: Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 73: 261-269, 2003
8)Irie F, Masaki KH, Petrovitch H, Abbott RD, Ross GW, et al: Apolipoprotein E epsilon4 allele genotype and the effect of depressive symptoms on the risk of dementia in men: the Honolulu-Asia Aging Study. Arch Gen Psychiatry 65: 906-912, 2008
9)Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D: Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63: 530-538, 2006
10)Byers AL, Yaffe K: Depression and risk of developing dementia. Nat Rev Neurol 7: 323-331, 2011
11)da Silva J, Goncalves-Pereira M, Xavier M, Mukaetova-Ladinska EB: Affective disorders and risk of developing dementia: systematic review. Br J Psychiatry 202: 177-186, 2013
12)Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd: Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry 202: 329-335, 2013
13)Boot BP, Orr CF, Ahlskog JE, Ferman TJ, Roberts R, et al: Risk factors for dementia with Lewy bodies: a case-control study. Neurology 81: 833-840, 2013
14)Green RC, Cupples LA, Kurz A, Auerbach S, Go R, et al: Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol 60: 753-759, 2003
15)Geerlings MI, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM: History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 70: 1258-1264, 2008
16)Kessing LV, Andersen PK: Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 75: 1662-1666, 2004
17)Dotson VM, Beydoun MA, Zonderman AB: Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 75: 27-34, 2010
18)Kessing LV, Olsen EW, Mortensen PB, Andersen PK: Dementia in affective disorder: a case-register study. Acta Psychiatr Scand 100: 176-185, 1999
19)Wu KY, Chang CM, Liang HY, Wu CS, Chia-Hsuan Wu E, et al: Increased risk of developing dementia in patients with bipolar disorder: a nested matched case-control study. Bipolar Disord 15: 787-794, 2013
20)Robinson RG, Starr LB, Kubos KL, Price TR: A two-year longitudinal study of post-stroke mood disorders: findings during the initial evaluation. Stroke 14: 736-741, 1983
21)Krishnan KR, Goli V, Ellinwood EH, France RD, Blazer DG, et al: Leukoencephalopathy in patients diagnosed as major depressive. Biol Psychiatry 23: 519-522, 1988
22)Fujikawa T, Yamawaki S, Touhouda Y: Incidence of silent cerebral infarction in patients with major depression. Stroke 24: 1631-1634, 1993
23)Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, et al: Clinically defined vascular depression. Am J Psychiatry 154: 562-565, 1997
24)Ylikoski R, Ylikoski A, Erkinjuntti T, Sulkava R, Raininko R, et al: White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol 50: 818-824, 1993
25)Salloway S, Malloy P, Kohn R, Gillard E, Duffy J, et al: MRI and neuropsychological differences in early- and late-life-onset geriatric depression. Neurology 46: 1567-1574, 1996
26)Kramer-Ginsberg E, Greenwald BS, Krishnan KR, Christiansen B, Hu J, et al: Neuropsychological functioning and MRI signal hyperintensities in geriatric depression. Am J Psychiatry 156: 438-444, 1999
27)Nakano Y, Baba H, Maeshima H, Kitajima A, Sakai Y, et al: Executive dysfunction in medicated, remitted state of major depression. J Affect Disord 111: 46-51, 2008
28)Yamashita H, Fujikawa T, Takami H,Yanai I, Okamoto Y, et al: Long-term prognosis of patients with major depression and silent cerebral infarction. Neuropsychobiology 62: 177-181, 2010
29)功刀 浩: うつ病を生物学的に理解する. 医学と薬学72: 1841-1849, 2015
30)Butters MA, Young JB, Lopez O, Aizenstein HJ, Mulsant BH, et al: Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci 10: 345-357, 2008
31)Sierksma AS, van den Hove DL, Steinbusch HW, Prickaerts J: Major depression, cognitive dysfunction and Alzheimer's disease: is there a link? Eur J Pharmacol 626: 72-82, 2010
32)Wolkowitz OM, Epel ES, Reus VI, Mellon SH: Depression gets old fast: do stress and depression accelerate cell aging? Depress Anxiety 27: 327-338, 2010
33)Rothman SM, Mattson MP: Adverse stress, hippocampal networks, and Alzheimer's disease. Neuromolecular Med 12: 56-70, 2010
34)O'Brien JT, Lloyd A, McKeith I, Gholkar A, Ferrier N: A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry 161: 2081-2090, 2004
35)Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 161: 1957-1966, 2004
36)Colla M, Kronenberg G, Deuschle M, Meichel K, Hagen T, et al: Hippocampal volume reduction and HPA-system activity in major depression. J Psychiatr Res 41: 553-560, 2007
37)Sheline YI, Gado MH, Kraemer HC: Untreated depression and hippocampal volume loss. Am J Psychiatry 160: 1516-1518, 2003
38)MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, et al: Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci U S A 100: 1387-1392, 2003
39)Elcombe EL, Lagopoulos J, Duffy SL, Lewis SJ, Norrie L, et al: Hippocampal volume in older adults at risk of cognitive decline: the role of sleep, vascular risk, and depression. J Alzheimers Dis 44: 1279-1290, 2015
40)Hickie I, Naismith S, Ward PB, Turner K, Scott E, et al: Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. Br J Psychiatry 186: 197-202, 2005
41)Steffens DC, McQuoid DR, Payne ME, Potter GG: Change in hippocampal volume on magnetic resonance imaging and cognitive decline among older depressed and nondepressed subjects in the neurocognitive outcomes of depression in the elderly study. Am J Geriatr Psychiatry 19: 4-12, 2011
42)Steffens DC, Payne ME, Greenberg DL, Byrum CE, Welsh-Bohmer KA, et al: Hippocampal volume and incident dementia in geriatric depression. Am J Geriatr Psychiatry 10: 62-71, 2002
43)Chi S, Yu JT, Tan MS, Tan L: Depression in Alzheimer's disease: epidemiology, mechanisms, and management. J Alzheimers Dis 42: 739-755, 2014
44)Caraci F, Copani A, Nicoletti F, Drago F: Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 626: 64-71, 2010
45)Krishnan V, Nestler EJ: The molecular neurobiology of depression. Nature 455: 894-902, 2008
46)Crochemore C, Lu J, Wu Y, Liposits Z, Sousa N, et al: Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 10: 790-798, 2005
47)Popp J, Schaper K, Kölsch H, Cvetanovska G, Rommel F, et al: CSF cortisol in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 30: 498-500, 2009
48)Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, et al: Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. Neurobiol Aging 36: 601-607, 2015
49)Notarianni E: Hypercortisolemia and glucocorticoid receptor-signaling insufficiency in Alzheimer's disease initiation and development. Curr Alzheimer Res 10: 714-731, 2013
50)Hoogendijk WJ, Meynen G, Endert E, Hofman MA, Swaab DF: Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression. Neurobiol Aging 27: 780.e1-780.e2, 2006
51)Zve^r^ová M, Fis^ar Z, Jirák R, Kitzlerová E, Hroudová J, et al: Plasma cortisol in Alzheimer's disease with or without depressive symptoms. Med Sci Monit 19: 681-689, 2013
52)Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM: Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 26: 9047-9056, 2006
53)Jacobs BL, van Praag H, Gage FH: Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 5: 262-269, 2000
54)Czéh B, Lucassen PJ: What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated? Eur Arch Psychiatry Clin Neurosci 257: 250-260, 2007
55)Van Bokhoven P, Oomen CA, Hoogendijk WJ, Smit AB, Lucassen PJ, et al: Reduction in hippocampal neurogenesis after social defeat is long-lasting and responsive to late antidepressant treatment. Eur J Neurosci 33: 1833-1840, 2011
56)Kim HK, Nunes PV, Oliveira KC, Young LT, Lafer B: Neuropathological relationship between major depression and dementia: A hypothetical model and review. Prog Neuropsychopharmacol Biol Psychiatry 67: 51-57, 2016
57)Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, et al: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54: 70-75, 2003
58)Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, et al: Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31: 1034-1037, 2007
59)Satomura E, Baba H, Nakano Y, Maeshima H, Suzuki T, et al: Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression. J Affect Disord 135: 332-335, 2011
60)Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, et al: Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 57: 1068-1072, 2005
61)Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, et al: Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109: 143-148, 2002
62)Takebayashi N, Maeshima H, Baba H, Nakano Y, Satomura E, et al: Duration of last depressive episode may influence serum BDNF levels in remitted patients with major depression. Depress Anxiety 29: 775-779, 2012
63)Aydemir O, Deveci A, Taneli F: The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 29: 261-265, 2005
64)Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT: Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 50: 260-265, 2001
65)Dwivedi Y: Involvement of brain-derived neurotrophic factor in late-life depression. Am J Geriatr Psychiatry 21: 433-449, 2013
66)Marano CM, Phatak P, Vemulapalli UR, Sasan A, Nalbandyan MR, et al: Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry 68: 512-517, 2007
67)Hashimoto K, Shimizu E, Iyo M: Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45: 104-114, 2004
68)Krishnan V, Nestler EJ: Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167: 1305-1320, 2010
69)Murer MG, Yan Q, Raisman-Vozari R: Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63: 71-124, 2001
70)Cotman CW: The role of neurotrophins in brain aging: a perspective in honor of Regino Perez-Polo. Neurochem Res 30: 877-881, 2005
71)Connor B, Young D, Yan Q, Faull RL, Synek B, et al: Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res 49: 71-81, 1997
72)Peng S, Wuu J, Mufson EJ, Fahnestock M: Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 93: 1412-1421, 2005
73)Carroll JC, Iba M, Bangasser DA, Valentino RJ, James MJ, et al: Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy. J Neurosci 31: 14436-14449, 2011
74)Sotiropoulos I: The neurodegenerative potential of chronic stress: a link between depression and Alzheimer's disease. Adv Exp Med Biol 822: 221-222, 2015
75)Sotiropoulos I, Catania C, Pinto LG, Silva R, Pollerberg GE, et al: Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits. J Neurosci 31: 7840-7847, 2011
76)Dong H, Murphy KM, Meng L, Montalvo-Ortiz J, Zeng Z, et al: Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease. J Alzheimers Dis 28: 579-592, 2012
77)Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM: Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A 104: 10673-10678, 2007
78)Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, et al: Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 63: 161-167, 2006
79)Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, et al: Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry 16: 168-174, 2008
80)van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM: Plasma Abeta (1-40) and Abeta (1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5: 655-660, 2006
81)Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, et al: Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64: 354-362, 2007
82)Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, et al: Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 73: 847-853, 2009
83)Giedraitis V, Sundelöf J, Irizarry MC, Gårevik N, Hyman BT, et al: The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett 427: 127-131, 2007
84)Pomara N, Doraiswamy PM, Willoughby LM, Roth AE, Mulsant BH, et al: Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem Res 31: 341-349, 2006
85)Sun X, Steffens DC, Au R, Folstein M, Summergrad P, et al: Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry 65: 542-550, 2008
86)Nascimento KK, Silva KP, Malloy-Diniz LF, Butters MA, Diniz BS: Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: a systematic review and meta-analysis. J Psychiatr Res 69: 35-41, 2015
87)Kita Y, Baba H, Maeshima H, Nakano Y, Suzuki T, et al: Serum amyloid beta protein in young and elderly depression: a pilot study. Psychogeriatrics 9: 180-185, 2009
88)Baba H, Nakano Y, Maeshima H, Satomura E, Kita Y, et al: Metabolism of amyloid-β protein may be affected in depression. J Clin Psychiatry 73: 115-120, 2012
89)Namekawa Y, Baba H, Maeshima H, Nakano Y, Satomura E, et al: Heterogeneity of elderly depression: increased risk of Alzheimer's disease and Aβ protein metabolism. Prog Neuropsychopharmacol Biol Psychiatry 43: 203-208, 2013
90)Direk N, Schrijvers EM, de Bruijn RF, Mirza S, Hofman A, et al: Plasma amyloid β, depression, and dementia in community-dwelling elderly. J Psychiatr Res 47: 479-485, 2013
91)Yamamoto K, Shimada H, Koh H, Ataka S, Miki T: Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer's disease. Geriatr Gerontol Int 14: 716-723, 2014
92)Inoue M, Baba H, Yamamoto K, Shimada H, Yamakawa Y, et al: Serum levels of albumin-amyloid β complex in patients with depression. Am J Geriatr Psychiatry［in press］
93)Piccinni A, Origlia N, Veltri A, Vizzaccaro C, Marazziti D, et al: Plasma β-amyloid peptides levels: a pilot study in bipolar depressed patients. J Affect Disord 138: 160-164, 2012
94)Gudmundsson P, Skoog I, Waern M, Blennow K, Pálsson S, et al: The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry 15: 832-838, 2007
95)Gudmundsson P, Skoog I, Waern M, Blennow K, Zetterberg H, et al: Is there a CSF biomarker profile related to depression in elderly women? Psychiatry Res 176: 174-178, 2010
96)Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, et al: Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 169: 523-530, 2012
97)Reis T, Brandão CO, Freire Coutinho ES, Engelhardt E, Laks J: Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: preliminary findings from Brazil. CNS Neurosci Ther 18: 524-529, 2012
98)Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, et al: Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord 22: 261-268, 2008
99)Madsen K, Hasselbalch BJ, Frederiksen KS, Haahr ME, Gade A, et al: Lack of association between prior depressive episodes and cerebral［11C］PiB binding. Neurobiol Aging 33: 2334-2342, 2012
100)Lavretsky H, Siddarth P, Kepe V, Ercoli LM, Miller KJ, et al: Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatry 17: 493-502, 2009
101)Kumar A, Kepe V, Barrio JR, Siddarth P, Manoukian V, et al: Protein binding in patients with late-life depression. Arch Gen Psychiatry 68: 1143-1150, 2011
102)Wu KY, Hsiao IT, Chen CS, Chen CH, Hsieh CJ, et al: Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography. Eur J Nucl Med Mol Imaging 41: 714-722, 2014
103)Wu KY, Liu CY, Chen CS, Chen CH, Hsiao IT, et al: Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study. Eur J Nucl Med Mol Imaging 43: 1067-1076, 2016
104)Tateno A, Sakayori T, Higuchi M, Suhara T, Ishihara K, et al: Amyloid imaging with［(18)F］florbetapir in geriatric depression: early-onset versus late-onset. Int J Geriatr Psychiatry 30: 720-728, 2015
105)Brendel M, Pogarell O, Xiong G, Delker A, Bartenstein P, et al: Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients. Eur J Nucl Med Mol Imaging 42: 716-724, 2015
106)功刀 浩: 精神栄養学—とくにうつ病との関連について. 臨床栄養（臨増）121: 488-493, 2012
107)Sofi F, Cesari F, Abbate R, Gensini GF, Casini A: Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337: a1344, 2008
108)Sofi F, Macchi C, Abbate R, Gensini GF, Casini A: Effectiveness of the Mediterranean diet: can it help delay or prevent Alzheimer's disease? J Alzheimers Dis 20: 795-801, 2010
109)Sánchez-Villegas A, Delgado-Rodríguez M, Alonso A, Schlatter J, Lahortiga F, et al: Association of the Mediterranean dietary pattern with the incidence of depression: the Seguimiento Universidad de Navarra/University of Navarra follow-up (SUN) cohort. Arch Gen Psychiatry 66: 1090-1098, 2009
110)Suzuki S, Akechi T, Kobayashi M, Taniguchi K, Goto K, et al: Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. Br J Cancer 90: 787-793, 2004
111)Gilbody S, Lightfoot T, Sheldon T: Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J Epidemiol Community Health 61: 631-637, 2007
112)Lawlor DA, Hopker SW: The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ 322: 763-767, 2001
113)Craft LL, Vaniterson EH, Helenowski IB, Rademaker AW, Courneya KS: Exercise effects on depressive symptoms in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 21: 3-19, 2012
114)Kessing LV, Søndergård L, Forman JL, Andersen PK: Antidepressants and dementia. J Affect Disord 117: 24-29, 2009
115)Kessing LV, Forman JL, Andersen PK: Do continued antidepressants protect against dementia in patients with severe depressive disorder? Int Clin Psychopharmacol 26: 316-322, 2011
116)Lee CW, Lin CL, Sung FC, Liang JA, Kao CH: Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study. J Clin Psychiatry 77: 117-122, 2016
117)Wang C, Gao S, Hendrie HC, Kesterson J, Campbell NL, et al: Antidepressant use in the elderly Is associated with an increased risk of dementia. Alzheimer Dis Assoc Disord 30: 99-104, 2016
118)Bali V, Holmes HM, Johnson ML, Chen H, Fleming ML, et al: Comparative effectiveness of second-generation antidepressants in reducing the risk of dementia in elderly nursing home residents with depression. Pharmacotherapy 36: 38-48, 2016
119)Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, et al: Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A 108: 14968-14973, 2011
120)Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, et al: Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30: 1125-1128, 2006
121)Nunes PV, Forlenza OV, Gattaz WF: Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 190: 359-360, 2007
122)Kessing LV, Søndergård L, Forman JL, Andersen PK: Lithium treatment and risk of dementia. Arch Gen Psychiatry 65: 1331-1335, 2008
123)Kessing LV, Forman JL, Andersen PK: Does lithium protect against dementia? Bipolar Disord 12: 87-94, 2010
124)Zhang X, Heng X, Li T, Li L, Yang D, et al: Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis 24: 739-749, 2011
125)Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, et al: Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198: 351-356, 2011
126) Inestrosa NC, Arenas E: Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11: 77-86, 2010
掲載誌情報
